Yonhap Infomax NewsOct 31
Celltrion has signed a joint R&D deal with MustBio to co-develop a triple fusion immuno-oncology drug, securing global rights in a contract worth up to 712.5 billion won ($525 million).
#YonhapInfomax #Celltrion #MustBio #ImmunoOncology #TripleFusionProtein #7125BillionWon #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=88603
Celltrion Signs Joint R&D Agreement with MustBio for Multi-Antibody Immuno-Oncology Drug

Celltrion has signed a joint R&D deal with MustBio to co-develop a triple fusion immuno-oncology drug, securing global rights in a contract worth up to 712.5 billion won ($525 million).

Yonhap Infomax